Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 4Withdrawn 3Terminated 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, T-Cell 3Recurrence 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Leukemia, Lymphoid 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

Rituximab 193Cyclophosphamide 177fludarabine phosphate 151Peripheral Blood Stem Cell Transplantation 89fludarabine 77Mycophenolic Acid 70Filgrastim 63Whole-Body Irradiation 59Tacrolimus 55Lenalidomide 54Cyclosporine 54ibrutinib 53Bendamustine Hydrochloride 50Busulfan 49Melphalan 45Radiotherapy 42Etoposide 42Alemtuzumab 42Antilymphocyte Serum 40ofatumumab 35obinutuzumab 33Methotrexate 33venetoclax 27Cytarabine 25sargramostim 23Granulocyte Colony-Stimulating Factor 22Dexamethasone 21Methylprednisolone 19Bortezomib 19Chlorambucil 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphocytic, Chronic, B-Cell × duvelisib × Clear all
NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

SecuraBio

Phase 3 Completed
319 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02049515 2023-09-21

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

SecuraBio

Phase 3 Completed
99 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡